Metrics to compare | NYR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNYRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −27.9x | −6.0x | −0.4x | |
PEG Ratio | 2.11 | −0.05 | 0.00 | |
Price/Book | 19.2x | 1.1x | 2.6x | |
Price / LTM Sales | 90.9x | 4.2x | 3.1x | |
Upside (Analyst Target) | −50.9% | 411.1% | 49.0% | |
Fair Value Upside | Unlock | 21.2% | 7.0% | Unlock |
Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.